AutoScreen: AI Agents Reprioritize CRISPR Hits, Reveal How Cancer Cells Evade Immune Attack
KexinHuang5 · x · 2026-09-26
Stanford's Le Cong lab and Phylo unveiled AutoScreen, an AI co-scientist system for target discovery.
- Problem: A CRISPR screen measures thousands of genes, but deciding which findings deserve follow-up experiments still requires manual synthesis of papers, pathways, and clinical evidence.
- Design: Five specialist agents handle literature research, question framing, biomedical resource search, synthesis, and candidate review, logging the evidence behind every ranking for auditability.
- Validation: Starting from a CRISPRa screen, AutoScreen re-prioritized lower-ranked candidates; wet-lab experiments confirmed that activating these genes increased cancer cells' resistance to primary human NK-cell killing, illuminating immune evasion.
- Context: Built by Yuanhao Qu (now at Phylo) as the capstone of his thesis work, following CRISPR-GPT; Le Cong is a scientific cofounder of Phylo, which also announced a seed round co-led by A16Z and Menlo Ventures and launched Biomni Lab.
More from Venture
- Alex Wang's Muse Partners with Plaid to Power Its AI Money Management App — alexandr_wang · 2026-09-26
- Investor argues agents should buy answers, not web fragments, challenging Cloudflare's microtransaction model — Ronangmi · 2026-09-26
- AMD hits $1T market cap: analyst argues it doesn't need to beat Nvidia to win through 2028 — Beth_Kindig · 2026-09-26
- Free Agent Readiness Tool Shows Exactly What GPTBot Sees on Your Site — cneuralnetwork · 2026-09-26
- Prediction: AGI Will Be Free for Most, With $150,000/Year Professional Tiers Like Bloomberg Terminals — BLUECOW009 · 2026-09-26
- Creator gets first X payout for AI-made series 'Age of Beyond' — chrisfirst · 2026-09-26